These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 16219009

  • 1. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents.
    Goodarzi MO, Bryer-Ash M.
    Diabetes Obes Metab; 2005 Nov; 7(6):654-65. PubMed ID: 16219009
    [Abstract] [Full Text] [Related]

  • 2. Metformin: old wine in new bottle--evolving technology and therapy in diabetes.
    Joshi SR.
    J Assoc Physicians India; 2005 Nov; 53():963-72. PubMed ID: 16515237
    [Abstract] [Full Text] [Related]

  • 3. [Metformin. Mode of action and effect of monotherapy and combination therapy on glucose metabolism in type 2 diabetes].
    Christiansen AL, Madsbad S.
    Ugeskr Laeger; 2002 Apr 08; 164(15):2025-8. PubMed ID: 11985000
    [Abstract] [Full Text] [Related]

  • 4. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P.
    Diabetes Obes Metab; 2008 Dec 08; 10(12):1167-77. PubMed ID: 18494804
    [Abstract] [Full Text] [Related]

  • 5. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.
    J Indian Med Assoc; 2008 Jul 08; 106(7):464-7. PubMed ID: 18975505
    [Abstract] [Full Text] [Related]

  • 6. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis.
    Monami M, Lamanna C, Marchionni N, Mannucci E.
    Diabetes Res Clin Pract; 2008 Feb 08; 79(2):196-203. PubMed ID: 17931733
    [Abstract] [Full Text] [Related]

  • 7. [Metformin role in the treatment of type 2 diabetes in 2008].
    Spada A, Philippe J.
    Rev Med Suisse; 2008 Jun 04; 4(160):1392-4, 1396-7. PubMed ID: 18630062
    [Abstract] [Full Text] [Related]

  • 8. The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes.
    Howlett H, Porte F, Allavoine T, Kuhn T, Nicholson G.
    Curr Med Res Opin; 2003 Jun 04; 19(3):218-25. PubMed ID: 12803736
    [Abstract] [Full Text] [Related]

  • 9. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin.
    Kadhim HM, Ismail SH, Hussein KI, Bakir IH, Sahib AS, Khalaf BH, Hussain SA.
    J Pineal Res; 2006 Sep 04; 41(2):189-93. PubMed ID: 16879326
    [Abstract] [Full Text] [Related]

  • 10. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B.
    Curr Med Res Opin; 2006 Sep 04; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [Abstract] [Full Text] [Related]

  • 11. Metformin in noninsulin-dependent diabetes mellitus.
    Lee AJ.
    Pharmacotherapy; 1996 Sep 04; 16(3):327-51. PubMed ID: 8726592
    [Abstract] [Full Text] [Related]

  • 12. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct 04; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 13. Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance.
    Mehnert H.
    Exp Clin Endocrinol Diabetes; 2001 Oct 04; 109 Suppl 2():S259-64. PubMed ID: 11460576
    [Abstract] [Full Text] [Related]

  • 14. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug 04; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 15. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb 04; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 16. Metformin: diamonds are forever.
    Papanas N, Maltezos E, Mikhailidis DP.
    Expert Opin Pharmacother; 2009 Oct 04; 10(15):2395-7. PubMed ID: 19678795
    [Abstract] [Full Text] [Related]

  • 17. Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
    Bosi E.
    Diabetes Obes Metab; 2009 May 04; 11 Suppl 2():3-8. PubMed ID: 19385978
    [Abstract] [Full Text] [Related]

  • 18. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M, Orsini-Federici M.
    Diabetes Care; 2008 Feb 04; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [Abstract] [Full Text] [Related]

  • 19. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M, Lam S.
    Cardiol Rev; 2007 Feb 04; 15(5):264-71. PubMed ID: 17700385
    [Abstract] [Full Text] [Related]

  • 20. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P.
    Diabetes Metab Res Rev; 2008 Feb 04; 24(1):3-13. PubMed ID: 17968971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.